Bristol-Myers Squibb Company (BMY)
Pretax margin
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | -8,394,000 | -6,891,000 | -6,432,000 | -5,859,000 | 8,425,000 | 8,607,000 | 8,683,000 | 8,778,000 | 7,695,000 | 7,697,000 | 7,641,000 | 7,238,000 | 8,078,000 | -4,231,000 | -4,131,000 | -4,056,000 | -6,891,000 | 3,435,000 | 2,520,000 | 2,667,000 |
| Revenue (ttm) | US$ in thousands | 48,300,000 | 47,435,000 | 46,509,000 | 45,534,000 | 45,006,000 | 44,935,000 | 45,187,000 | 45,848,000 | 46,159,000 | 46,738,000 | 47,144,000 | 46,960,000 | 46,385,000 | 45,468,000 | 44,384,000 | 42,810,000 | 42,518,000 | 39,395,000 | 34,862,000 | 31,006,000 |
| Pretax margin | -17.38% | -14.53% | -13.83% | -12.87% | 18.72% | 19.15% | 19.22% | 19.15% | 16.67% | 16.47% | 16.21% | 15.41% | 17.42% | -9.31% | -9.31% | -9.47% | -16.21% | 8.72% | 7.23% | 8.60% |
December 31, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-8,394,000K ÷ $48,300,000K
= -17.38%
The pretax margin of Bristol-Myers Squibb Company has experienced fluctuations over the period from March 31, 2020, to December 31, 2024.
The company's pretax margin started positively at 8.60% in March 2020, showing profitability before taxes. However, there was a decline in profitability, with margins dropping to 7.23% by June 2020. The trend reversed, showing improvement with a pretax margin of 8.72% in September 2020.
By December 2020, the pretax margin significantly turned negative, recording a drastic decline to -16.21%, reflecting potential operational challenges or one-time charges impacting profitability. This negative trend continued in the subsequent quarters, with pretax margins at -9.47% and -9.31% in March and June 2021, respectively.
Despite this, the company's performance improved in the following periods, with a notable recovery in profitability. By December 2021, Bristol-Myers Squibb recorded a significantly high pretax margin of 17.42%, which then continued to increase to 19.15% in March 2023.
However, there was a downward shift in pretax margin to 18.72% by December 2023, followed by a negative trend in the next periods, with margins falling to -12.87%, -13.83%, -14.53%, and -17.38% in March, June, September, and December 2024, respectively. These negative margins might indicate challenges impacting the company's bottom line during those quarters.
Overall, while Bristol-Myers Squibb Company demonstrated fluctuations in its pretax margin over the analyzed period, it showcased both positive and negative trends in profitability, reflecting the company's financial performance and operational efficiency during the specified timeframe.
Peer comparison
Dec 31, 2024